Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Cidara Therapeutics, Inc. CDTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
33/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$57.00
-74.3%

Cidara Therapeutics, Inc. (CDTX) is a Biotechnology company in the Healthcare sector, currently trading at $221.38. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is CDTX = $57 (-74.3% upside).

Financials: revenue is $1M, -23%/yr average growth. Net income is $170M (loss), growing at -195.1%/yr. Net profit margin is -13319.8% (negative). Gross margin is 81.7% (-17.9 pp trend).

Balance sheet: total debt is $4M against $163M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.25 (strong liquidity). Debt-to-assets is 1.7%. Total assets: $215M.

Analyst outlook: 8 / 11 analysts rate CDTX as buy (73%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 47/100 (Partial), Future 49/100 (Partial), Income 10/100 (Fail).

$57.00
▼ 74.25% Downside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Cidara Therapeutics, Inc., the average price target is $57.00, with a high forecast of $68.00, and a low forecast of $46.00.
Highest Price Target
$68.00
Average Price Target
$57.00
Lowest Price Target
$46.00

CDTX SharesGrow Score Overview

39/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 47/100
Gross margin is + market cap
FUTURE 49/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CDTX

✗
VALUE Fail
10/100
CDTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $57, implying -74.3% from the current price $221. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CDTX: -23%/yr revenue is, -195.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet CDTX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 4.25 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
47/100
CDTX: Gross margin is 81.7% (-17.9 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 47/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
49/100
Analyst outlook: 8 / 11 analysts rate CDTX as buy (73%). Analyst consensus target is $57 (-74.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CDTX: Net profit margin is -13319.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range15.22-221.42
Volume2.69M
Avg Volume (30D)1.37M
Market Cap$5.61B
Beta (1Y)1.53
Share Statistics
EPS (TTM)-26.75
Shares Outstanding$6.35M
IPO Date2015-04-15
Employees38
CEOJeffrey L. Stein
Financial Highlights & Ratios
Revenue (TTM)$1.28M
Gross Profit$1.04M
EBITDA$-176.1M
Net Income$-169.83M
Operating Income$-176.1M
Total Cash$189.83M
Total Debt$3.58M
Net Debt$-186.25M
Total Assets$214.8M
Price / Earnings (P/E)-8.3
Price / Sales (P/S)4402.96
Analyst Forecast
1Y Price Target$57.00
Target High$68.00
Target Low$46.00
Upside-74.3%
Rating ConsensusBuy
Analysts Covering11
Buy 73% Hold 27% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS1717572069

Price Chart

Track all markets on TradingView
CDTX
Cidara Therapeutics, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
15.22 52WK RANGE 221.42

People Also View

GLYC
GLYC
GlycoMimetics, Inc.
$15.71
-2.76%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 CLSD
CLSD
Clearside Biomedical, Inc.
$0.41
+0.00%
 TCON
TCON
TRACON Pharmaceuticals, Inc.
$0.03
+0.00%
 CFRX
CFRX
ContraFect Corporation
$0.05
-27.95%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message